Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China flag China · Delayed Price · Currency is CNY
30.05
+0.65 (2.21%)
Aug 21, 2026, 3:00 PM CST

SHA:688319 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-23.8222.2620.7617.5626.58107.96
Depreciation & Amortization
41.9937.7232.4730.8125.323.04
Other Amortization
4.45.343.533.153.431.64
Loss (Gain) From Sale of Assets
--0.010.030.150.150.01
Asset Writedown & Restructuring Costs
-4.04-----
Loss (Gain) From Sale of Investments
-0.47-0.5-0.86-1.04-3.7-3.76
Provision & Write-off of Bad Debts
-18.8713.2110.191.7212.189
Other Operating Activities
36.328.046.675.669.130.12
Change in Accounts Receivable
-79.49-84.65-83.630.98-151.92-147.16
Change in Inventory
1.869.71-13.571.68-7.96-27.28
Change in Accounts Payable
99.6575.1319.06-12.364.4681.2
Operating Cash Flow
54.83105.49-9.7344-24.5539.96
Operating Cash Flow Growth
93.34%----89.49%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-84.15-98.81-207.32-169.88-200.69-69.71
Sale of Property, Plant & Equipment
-0.030.03--0.01
Investment in Securities
-24.11-24.21-17.590140-190
Other Investing Activities
0.470.50.861.043.73.76
Investing Cash Flow
-107.79-122.49-223.93-78.84-56.99-255.94

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-176.1206.82208.25129.9935
Total Debt Issued
215.1176.1206.82208.25129.9935
Long-Term Debt Repaid
--119.65-78.85-100.06-40-27.34
Total Debt Repaid
-90.78-119.65-78.85-100.06-40-27.34
Net Debt Issued (Repaid)
124.3256.45127.97108.1989.997.66
Issuance of Common Stock
---10.3817.65371.81
Repurchase of Common Stock
-2.38-2.38-2.39---
Common Dividends Paid
-19.5-14.72-29.68-5.99-4.25-1.03
Other Financing Activities
-22.97-14.95-16.68--9.64
Financing Cash Flow
79.4824.495.91129.27103.38368.79

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
26.527.4-137.7694.4221.84152.82

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-29.326.68-217.05-125.88-225.24-29.75
Free Cash Flow Growth
------
Free Cash Flow Margin
-3.86%0.95%-36.86%-25.37%-41.14%-6.11%
Free Cash Flow Per Share
-0.070.02-0.54-0.31-0.56-0.08
Levered Free Cash Flow
20.6913.44-200.57-140.57-198.44-67.11
Unlevered Free Cash Flow
25.3622.81-191.53-136.09-195.27-66.34

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
137.9152.1425.5934.193516.56
Change in Working Capital
19.34-0.57-82.52-14-97.61-98.05